HopeStage
Back to all studies
CompletedNCT02577250

Ketamine Infusions for PTSD and Treatment-Resistant Depression

About this titleRead the official source — NCT02577250
Medication studyAges 18–75United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 75 years.

What did participation involve?

The study group receives ketamine as a study medication.

Listed locations
MinneapolisSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2015
Recruitment status
Completed
Enrollment listed in the registry
20
Sponsor
Minneapolis Veterans Affairs Medical Center
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT02577250
Official title
Show the full official title

Efficacy and Safety of Repeated Intravenous Subanesthetic Ketamine Infusions Among Veterans With Treatment Resistant Depression Comorbid With Chronic Post-Traumatic Stress Disorder: A Proof-of-concept Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Minneapolis

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Minneapolis Veterans Affairs Medical Center, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including ketamine.

Who was this study for?

Listed age limits: 18 years to 75 years.

Want to explore more studies?

Explore studies